Related Experiment Video
Updated: May 4, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
Bernard R Lauwerys1, Julie Ducreux2, Frédéric A Houssiau3
1Pôle de Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Service de Rhumatologie, Clinique Universitaire Saint-Luc, Bruxelles, Belgium.Pôle de Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Service de Rhumatologie, Clinique Universitaire Saint-Luc, Bruxelles, Belgium. Bernard.Lauwerys@uclouvain.be.
Abstract:
SLE is an autoimmune condition characterized by loss of tolerance to chromatin constituents and the production of ANAs. The majority of SLE patients display spontaneous expression of type I IFN-induced genes in circulating mononuclear cells and peripheral tissues, and type I IFNs play a role in the pathogenesis of the disease via the sustained activation of autoreactive T and B cells necessary for the production of pathogenic autoantibodies. Several IFN-blocking strategies are currently being evaluated in clinical trials: monoclonal antibodies directed against IFN-α and type I IFN-α receptor (IFNAR), as well as active immunization against IFN-α. This review describes the rationale behind these trials and the results obtained, and discusses the perspectives for further development of these drugs.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

